Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$164.99 USD

164.99
4,600,299

-2.37 (-1.42%)

Updated Sep 5, 2024 04:00 PM ET

After-Market: $164.96 -0.03 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?

Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

STERIS (STE) Q4 Earnings Beat Estimates, Gross Margin Falls

Heading into fiscal 2024, STERIS (STE) expects many of its fiscal 2023 challenges to abate, including procedure volumes and supply chain constraints.

Haemonetics (HAE) Q4 Earnings and Revenues Top Estimates

Amid a challenging economic environment, Haemonetics (HAE) delivers impressive fiscal fourth-quarter organic revenues, led by the stellar performance across the Plasma and Hospital business.

Alcon (ALC) Q1 Earnings Surpass Estimates, 23' EPS View Up

Alcon (ALC) Q1 revenues were driven by strong consumables and equipment sales.

Here's Why You Should Retain Walgreens Boots (WBA) For Now

Investors are optimistic about Walgreens Boots (WBA) on consistent partnership growth and a strong focus on strategic execution.

Charles River (CRL) Q1 Earnings Top Estimates, View Narrowed

Charles River (CRL) registers robust growth in small research models, research model services and the Cell Solutions business.

NuVasive (NUVA) Q1 Earnings Beat Estimates, Margins Fall

NuVasive's (NUVA) strong sales across the U.S. Spinal Hardware and U.S. Surgical Support businesses instill optimism.

Syneos Health (SYNH) Tops Q1 Earnings, Announces Merger Plan

Syneos Health's (SYNH) first-quarter 2023 earnings and revenues beat estimates. The company enters into a definitive merger agreement to be acquired by a private investment consortium.

Should You Invest in the Vanguard Health Care ETF (VHT)?

Sector ETF report for VHT

Halozyme (HALO) Q1 Earnings Disappoint, Revenues Rise Y/Y

Halozyme (HALO) first-quarter earnings and revenues miss estimates. The company reiterates its guidance for 2023.

SmileDirectClub (SDC) Q1 Earnings Miss, Gross Margin Up

SmileDirectClub (SDC) Q1 revenues are affected by persistent macroeconomic headwinds.

Emergent (EBS) Q1 Earnings Miss Estimates, Revenues Beat

Emergent (EBS) reports wider-than-expected first-quarter loss. The company updates its 2023 guidance for selected categories.

Exact Sciences (EXAS) Q1 Earnings Top, Sales View Raised

The upside in Exact Sciences' (EXAS) screening revenues is primarily coming from broad-based momentum in Cologuard adoption.

Sweta Killa headshot

Pharma ETFs Gain Post Q1 Earnings

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. As such, pharma ETFs have been in the green over the past month.

Henry Schein (HSIC) Q1 Earnings Miss, Operating Margin Dips

Henry Schein's (HSIC) first-quarter results largely reflect lower contributions from the sales of PPE products and COVID-19 test kits.

Omnicell's (OMCL) New Acquisitions Aid Growth, Cost Woes Stay

Omnicell (OMCL) remains well-positioned to meet pharmacy and hospital needs, backed by the recent acquisitions and expansion of its advanced services solutions.

Bruker's (BRKR) New Buyout to Advance Digital Transformation

Bruker's (BRKR) IDS division expands its unique vendor-agnostic software solutions portfolio by integrating ZONTAL with the Mestrelab Research and Arxspan scientific software solutions.

Here's Why You Should Retain Abbott (ABT) Stock For Now

Investors are optimistic about Abbott (ABT) on continued growth in the core Diagnostics arm.

Teleflex (TFX) Q1 Earnings Top Estimates, 2023 Sales View Up

Teleflex (TFX) registers growth across the majority of its businesses, including double-digit increases in interventional and surgical revenues in Q1.

Globus Medical (GMED) Q1 Earnings Beat, Operating Margin Dips

The significant year-over-year surge in Globus Medical's (GMED) Enabling Technologies sales is driven by ongoing demand for the company's robotics and imaging system technologies.